A review of data in the literature sought to determine whether these procedures have a role in managing vertebral metastasis and subsequent pathological vertebral fractures in patients with MM.
Researchers sought to determine whether extramedullary lesions would be an indicator of prognosis in patients with multiple myeloma treated in the first line with bortezomib.
A case report describes an atypical presentation of multiple myeloma marked by immunogammopathy maculopathy and hyperviscosity syndrome-related retinopathy.
Researchers sought to determine which of 2 combination regimens would be a more effective treatment for patients with relapsed/refractory multiple myeloma.
Patients who received daratumumab were more likely to be MRD negative at 12 months and beyond.